Mymetics regains intra-nasal influenza vaccine from Solvay
Mymetics has provided license of its intra-nasal flu vaccine, under which Solvay has developed the vaccine until 2008 and also completed phase I trial. The results demonstrated that
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.